Status and phase
Conditions
Treatments
About
This study is a phase II single-arm clinical study.The purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with apatinib mesylate and standard chemotherapy (pemetrexed plus carboplatin) in patients with advanced non-squamous and non-small cell lung cancer who have failed tyrosine kinase inhibitor therapy and are ALK-positive.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 18 - 75 year,male or female;
Subjects with histologically or cytologically confirmed advanced non-squamous non-small cell lung cancer, imaging stage IIIb~IV;
ALK fusion gene is positive and meets the following conditions:
Patients with at least one evaluable or measurable lesions as per RECIST version 1.1;
Patients who have not previously received systematic chemotherapy for advanced lung cancer .Can also be enrolled if you have previously received Neoadjuvant or adjuvant therapy;
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Survival expectation ≥ 3 months;
Women of childbearing age must have a serum pregnancy study within 2 weeks prior to the first dose and the results are negative. Female subjects of childbearing age and partners who are women of childbearing age must be contraceptive during the study period and within 180 days after the last administration of the study drug;
The laboratory test value of the patient before medication should meet the following standards:
Subjects voluntarily joined the study, signed informed consent, good compliance, and followed up;
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
59 participants in 1 patient group
Loading...
Central trial contact
Jingxun Wu, doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal